Large RCC database answers key prognostic questions

Los Angeles--The largest clinical database built on renal cell carcinoma is beginning to yield definitive answers to questions about prognosis and treatment. Analyses of histories of more than 4,000 patients at eight academic medical centers worldwide has already indicated that tumor stage, grade, and performance status have a stronger influence on prognosis than tumor stage alone and that the indications for partial nephrectomy can expand.

Related Videos

Related Content

Advertisement

December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke

“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

November 27th 2024

Phase 2 trial launches of autologous prostate cancer vaccine

Hannah Clarke

The phase 2 CELLVX-230 trial is exploring the potential of FK-PC101 to delay or prevent prostate cancer recurrence following prostatectomy.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 26th 2024

Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC

Hannah Clarke

“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says Jacob E. Berchuck, MD.

November 26th 2024

UGN-101 demonstrates long-term durability in low-grade UTUC

Hannah Clarke

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says Phillip Pierorazio, MD.

Related Content

Advertisement

December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke

“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

November 27th 2024

Phase 2 trial launches of autologous prostate cancer vaccine

Hannah Clarke

The phase 2 CELLVX-230 trial is exploring the potential of FK-PC101 to delay or prevent prostate cancer recurrence following prostatectomy.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 26th 2024

Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC

Hannah Clarke

“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says Jacob E. Berchuck, MD.

November 26th 2024

UGN-101 demonstrates long-term durability in low-grade UTUC

Hannah Clarke

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says Phillip Pierorazio, MD.